Stryker (SYK)
Pairs orthopaedic implants with Mako robotics, surgical equipment and vascular devices.
Something off on this page? Send us feedback.
Sells orthopaedic implants, Mako robotic systems, surgical instruments, endoscopy equipment, hospital-care technology, neurocranial devices and vascular tools across Orthopaedics and MedSurg and Neurotechnology. Most revenue comes from U.S. hospitals and clinicians, with implants paired to the instruments, navigation and robotics used in procedures.
Runs Orthopaedics and MedSurg and Neurotechnology businesses spanning implants, procedure technology and hospital equipment. Orthopaedics covers knees, hips, trauma and extremities; Ortho Tech groups Mako robotics and enabling technologies with power tools and cutting accessories.
MedSurg and Neurotechnology includes surgical instruments and navigation, endoscopy, patient handling, emergency and intensive-care products, clinical communications and virtual-care software, neurocranial devices, and vascular tools for stroke and venous thromboembolism. Inari broadened clot-removal offerings, while the spinal-implant business was sold.
Pairs implants with the instruments, planning software and robotic systems used in procedures, while most products are marketed directly to hospitals and clinicians. The United States supplies most sales, with additional business across Europe, the Middle East, Africa and Asia-Pacific. Product launches depend on regulatory review, while reimbursement and healthcare cost-containment measures shape adoption and pricing.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 18, 2026 | Canaccord Genuity | Reiterate | Rating: —Target: $400 | Target: $385 |
| Sep 9, 2026 | BMO Capital | Reiterate | Rating: —Target: $369 | Target: $317 |
| Sep 9, 2026 | Wells Fargo | Reiterate | Rating: —Target: $286 | Target: $348 |
| Aug 13, 2026 | Wolfe Research | Downgrade | ||
| Jul 31, 2026 | RBC Capital | Reiterate | Rating: —Target: $435 | Target: $420 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $3.48B · Total debt $14.94B · Total assets $47.93B · Shareholders' equity $23.99B
- Revenue
- $6.59B
- Operating income
- $1.66B
- Net income
- $1.28B
HistoryDividendAnnual yieldUpcoming
| Institutions | 80.79% | 309.89M shares | |
|---|---|---|---|
| 2,330 holders · as of Jun 30, 2026 | |||
| Insiders | 5.38% | 20.63M shares | |
| 25 holders · as of Sep 8, 2026 | |||
| Other | 13.83% | 53.05M shares | |
| remainder | |||
383.57M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 7.15% | 27.41M | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 5.88% | 22.54M | as of Jun 30, 2026 |
John W. BrownInsider | 5.23% | 20.06M | filed Feb 9, 2021 |
JPMorgan Chase & CoInstitution | 4.50% | 17.26M | as of Jun 30, 2026 |
State Street CorpInstitution | 4.05% | 15.53M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Nov 22, 2022 | Mary K. Brainerd | director | +18 | $225.20 |
| Jun 12, 2020 | Mary K. Brainerd | director | +3 | $185.65 |
| May 12, 2020 | Mary K. Brainerd | director | +36 | $193.21 |
| Sep 12, 2019 | Mary K. Brainerd | director | +11 | $221.03 |
| Jun 26, 2019 | Mary K. Brainerd | director | +63 | $202.21 |
- Johnson & Johnson
Broadest rival: ortho implants, Velys robotics, instruments, neurovascular.
- Zimmer Biomet
Pure-play ortho implants and ROSA robotics — head-to-head in knees and hips.
- Medtronic
Broad rival: instruments, spine robotics, neurovascular, and patient monitoring.
- Smith & Nephew (ADR)
Ortho implants, CORI robotics, sports medicine — named rival in two segments.
- Boston Scientific
Vascular rival; Penumbra deal creates head-to-head contest with Inari in VTE.
- Globus Medical
Spine implants and ExcelsiusGPS robotics — #2 global spine rival to K2M.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Stryker | $276.05 | +0.68% | $105.11B | 28.4 | 17.2 | 4.1 | +9.4% |
| Johnson & Johnson | $267.30 | −0.81% | $649.40B | 31.2 | 22.5 | 6.6 | +6.6% |
| Zimmer Biomet | $94.52 | +0.21% | $18.25B | 22.9 | 10.8 | 2.1 | +4.8% |
| Medtronic | $91.47 | −0.31% | $117.44B | 22.6 | 15.2 | 3.1 | +13.7% |
| Smith & Nephew (ADR) | $27.64 | −0.18% | $11.63B | 19.0 | — | 1.8 | +4.6% |
| Boston Scientific | $44.60 | +2.01% | $64.98B | 17.8 | 13.6 | 3.1 | +7.5% |
| Globus Medical | $74.77 | +0.65% | $10.02B | 19.1 | 14.6 | 3.2 | +5.9% |
| Median | 20.8 | 14.6 | 3.1 | +6.3% |